Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

160
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

148
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Si et al. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. <i>Pharmaceutics</i> 2020, <i>12</i>, 1079.

Pharmaceutics·2025
Same author

mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer.

Cancer research·2024
Same author

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.

Cancer research·2024
Same author

Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. <i>Biomedicines</i> 2022, <i>10</i>, 130.

Biomedicines·2024
Same author

IndGOterm: a qualitative method for the identification of individually dysregulated GO terms in cancer.

Briefings in bioinformatics·2022
Same author

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma.

Biomedicines·2022

Related Experiment Video

Updated: Apr 23, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K

Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.

Zhuoxin Zhou1, Davis Ballard1, Jiashuai Zhang2

  • 1Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio.

Cancer Research Communications
|April 21, 2026
PubMed
Summary
This summary is machine-generated.

We developed novel dual-payload antibody-drug conjugates (DualADCs) for triple-negative breast cancer (TNBC) that combine chemotherapy and immunotherapy. A DualADC with deruxtecan and imidazoquinoline showed superior antitumor efficacy and low toxicity in preclinical models.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Area of Science:

  • Oncology
  • Immunology
  • Bioconjugation Chemistry

Background:

  • Antibody-drug conjugates (ADCs) are effective cancer therapeutics.
  • Triple-negative breast cancer (TNBC) requires novel treatment strategies.
  • Simultaneous delivery of chemotherapy and immunotherapy offers a promising approach.

Purpose of the Study:

  • To develop novel dual-payload ADCs (DualADCs) for TNBC treatment.
  • To engineer ADCs capable of delivering both a chemotherapeutic agent and an immunotherapy agent.
  • To evaluate the efficacy and safety of these DualADCs in preclinical TNBC models.

Main Methods:

  • Developed two-site (cysteine and lysine) co-conjugation technologies for ADCs.
  • Created humanized anti-CD276 (B7-H3) mAb-based DualADCs.
  • Characterized DualADCs using analytical tools and assessed in vitro/in vivo efficacy and toxicity.

Main Results:

  • DualADCs demonstrated high affinity and selectivity for TNBC with minimal off-target effects.
  • In vitro studies showed high cancer cell binding, internalization, and cytotoxicity.
  • In vivo studies identified a DualADC with deruxtecan and imidazoquinoline as having the best antitumor efficacy, favorable biodistribution, and low systemic toxicity.

Conclusions:

  • Established advanced dual-payload antibody-drug conjugation technologies.
  • Identified a promising DualADC candidate for targeted cancer chemoimmunotherapy.
  • DualADCs represent a novel therapeutic strategy for aggressive cancers like TNBC.